From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

Long-Term Study Highlights Limitations of Current TTP Diagnostic Methods

For the past two decades, ADAMTS13 activity has been the backbone of diagnosis for thrombotic thrombocytopenic purpura (TTP); however, a long-term registry study published...
WIB_icon

Predicting Survival Outcomes for Children With Down Syndrome and AML or MDS

Children with Down syndrome (DS) have a higher risk of developing acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) than those without DS....
WIB_icon

Weighing the Risks and Benefits of Nivolumab in Patients With Hodgkin Lymphoma Undergoing AlloHCT

For patients with Hodgkin lymphoma (HL), allogeneic hematopoietic cell transplantation (alloHCT) can induce long-term disease control; however, relapse is common and rates of 3-year...
WIB_icon

Pembrolizumab Induces Remission in Small Cohort of Patients With Natural Killer/T-Cell Lymphomas

For the 20 to 40 percent of patients with natural killer (NK)/T-cell lymphomas who do not respond to regimens such as SMILE (dexamethasone, methotrexate,...
WIB_icon

Venetoclax Plus Obinutuzumab Effective in Older Adults With CLL and Comorbidities

Patients with chronic lymphocytic leukemia (CLL) are often older at the time of diagnosis (median age = 72 years), and typically receive treatment for...
WIB_icon

Is Ibrutinib Tied to Ventricular Arrhythmias?

Previous studies have indicated that treatment with ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is associated with a 5 to 15 percent increase in...

Investigating Trends in Survival Outcomes Among the Oldest Patients with DLBCL

The probability of developing non-Hodgkin lymphoma (NHL) increases with age. Thus, as the U.S. population ages, a greater number of patients are at risk...
WIB_icon

Can Pomalidomide Plus Dexamethasone “Rescue” Patients With Relapsed/ Refractory Amyloid Light-Chain Amyloidosis?

Patients with amyloid light-chain (AL) amyloidosis are often treated upfront with combinations of alkylating agents and bortezomib; when they don’t respond to this regimen...
WIB_icon

Encouraging Trends in Six-Month Mortality in Amyloid Light-Chain Amyloidosis

With recent advances in diagnosis, treatment, and response assessment, clinicians have observed a significant decrease in six-month mortality (p<0.001) among patients with amyloid light-chain...
WIB_icon

Can Podoplanin Explain the Connection Between Brain Tumors and Venous Thromboembolism?

Podoplanin, a sialomucin-like glycoprotein that can induce blood platelet activation, is frequently expressed by primary brain tumors. Its overexpression can contribute to a greater...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.